| Literature DB >> 29607389 |
Femke Crouwel1, M M Meurs-Szojda1, M Klemt-Kropp1, P Fockens2, M E Grasman1.
Abstract
BACKGROUND AND STUDY AIMS: Since the introduction of open-access esophago-gastroduodenoscopy (OAE) there is an increase in the total number of performed OAEs whilst the frequency of clinical relevant findings has decreased. The aim of this study was to assess the appropriate use and the diagnostic yield of OAE in the Netherlands and to determine which patient variables are able to predict a malignant finding. PATIENTS AND METHODS: A retrospective chart review of all referrals for diagnostic OAE between October 2012 and October 2016 at the Northwest Clinics was performed. The indications were recorded from the referral letter and were classified as "appropriate" or "inappropriate" according to the NHG guideline. Logistic regression was used to detect significant predictive variables for a malignancy.Entities:
Year: 2018 PMID: 29607389 PMCID: PMC5876021 DOI: 10.1055/s-0043-123185
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Referral indications divided in 4 groups, of which the first three groups are considered appropriate referral indications and the last group is considered inappropriate according to the NHG guideline.
|
| |||
|
|
|
|
|
| Dysphagia | Follow-up of gastric ulcer healing | Persistent or recurrent dyspepsia older than age 50 with a negative H. pylori status | Dyspepsia younger than age 50 without alarm symptoms |
| Unexplained weight loss | First-degree relative older than age 40 of a patient with familial gastric cancer | Persistent or recurrent dyspepsia older than age 50 with unknown H. pylori status | |
| Gastrointestinal bleeding | Familial esophageal cancer | ||
| Anemia | Reassurance | ||
| Persistent vomiting | |||
Relative risk of finding a malignancy, a benign finding with clinical relevance and a benign finding without clinical relevance for every referral indication. Wherein patients with the referral indication are compared to patients without the referral indication.
|
| |||||||
|
|
|
|
|
| |||
|
|
|
|
|
|
| ||
|
| 1195 (59.6 %) | 100 (5.0 %) |
17.0 (6.3 – 45.91)
| 264 (13.2 %) |
1.44 (1.19 – 1.75)
| 831 (41.4 %) |
0.83 (0.79 – 0.87)
|
| Alarm symptoms overall | 797 (39.7 %) | 94 (4.7 %) |
14.26 (7.48 – 27.20)
| 200 (10.0 %) |
1.61 (1.35 – 1.93)
| 503 (25.0 %) |
0.75 (0.71 – 0.80)
|
| Dysphagia | 420 (20.9 %) | 38 (1.9 %) |
2.17 (1.48 – 3.19)
| 113 (5.6 %) |
1.55 (1.28 – 1.88)
| 269 (13.4 %) |
0.82 (0.76 – 0.88)
|
| Weight loss | 104 (5.2 %) | 10 (0.5 %) |
1.95 (1.05 – 3.62)
| 21 (1.0 %) | 1.05 (0.71 – 1.55) | 73 (3.7 %) | 0.93 (0.82 – 1.05) |
| Gastrointestinal bleeding | 92 (4.6 %) | 4 (0.2 %) | 0.83 (0.31 – 2.21) | 22 (1.1 %) | 1.25 (0.86 – 1.82) | 66 (3.3 %) | 0.95 (0.83 – 1.08) |
| Anaemia | 31 (1.5 %) | 2 (0.1 %) | 1.25 (0.32 – 4.84) | 9 (0.4 %) | 1.51 (0.87 – 2.64) | 20 (1 %) | 0.85 (0.66 – 1.11) |
| Dysphagia and weight loss | 121 (6.0 %) | 34 (1.7 %) |
7.57 (5.25 – 10.91)
| 28 (1.4 %) | 1.21 (0.86 – 1.70) | 59 (2.9 %) |
0.64 (0.54 – 0.78)
|
| Weight loss and gastrointestinal bleeding | 12 (0.6 %) | 1 (0.05 %) | 1.61 (0.24 – 10.64) | 4 (0.2 %) | 1.73 (0.77 – 3.87) | 7 (0.35 %) | 0.77 (0.48 – 1.25) |
| Dyspepsia > 50 years of age, HP negative | 383 (19.1 %) | 6 (0.4 %) |
0.26 (0.11 – 0.59)
| 62 (3.5 %) | 0.81 (0.63 – 1.03) | 315 (15.2 %) |
1.11 (1.05 – 1.18)
|
| Other | 32 (1.6 %) | 5 (0.25 %) |
3.12 (1.36 – 7.13)
| 5 (0.25 %) | 0.81 (0.36 – 1.81) | 22 (1.1 %) | 0.91 (0.72 – 1.15) |
|
| 811 (40.4 %) | 4 (0.2 %) |
0.06 (0.02 – 0.16)
| 124 (6.2 %) |
0.69 (0.57 – 0.84)
| 683 (34.0 %) |
1.21 (1.15 – 1.27)
|
| Dyspepsia < 50 years of age | 373 (18.6 %) | 0 (0 %) |
0.02 (0.00 – 0.34)
| 39 (1.9 %) |
0.49 (0.36 – 0.67)
| 334 (16.7 %) |
1.24 (1.18 – 1.30)
|
| Dyspepsia > 50 years of age, HP unknown | 427 (21.3 %) | 4 (0.2 %) |
0.15 (0.05 – 0.40)
| 82 (4.2 %) | 0.99 (0.80 – 1.23) | 341 (16.9 %) |
1.08 (1.02 – 1.14)
|
| Other | 11 (0.5 %) | 0 (0 %) | 0.80 (0.05 – 12.08) | 3 (0.1 %) | 1.41 (0.54 – 3.73) | 8 (0.4 %) | 0.96 (0.67 – 1.38) |
|
| 2006 (100 %) | 104 (5.2 %) | 388 (19.3 %) | 1514 (75.5 %) | |||
Only the indications occurring with a frequency > 0.5 % were extensively reported
P < 0.05
Odds ratio of different endoscopic outcomes in OAEs performed for an appropriate referral indication.
|
|
|
|
|
|
|
|
|
| 104 (5.2 %) | 100 (5 %) | 4 (0.2 %) | 18.425 | 6.754 – 50.260 | < 0.0001 |
| Esophageal carcinoma | 82 (4.1 %) | 79 (3.9 %) | 3 (0.2 %) | 19.066 | 5.998 – 60.601 | < 0.0001 |
| Malignancies of the stomach | 21 (1.05 %) | 20 (1 %) | 1 (0.05 %) | 13.787 | 1.847 – 102.935 | 0.011 |
| Malignant tumors of the duodenum | 1 (0.05 %) | 1 (0.05 %) | 0 (0 %) | |||
|
| 388 (19.3 %) | 264 (13.2 %) | 124 (6.1 %) | 1.571 | 1.242 – 1.987 | < 0.0001 |
| Reflux esophagitis grade A | 12 (0.6 %) | 5 (0.25 %) | 7 (0.35 %) | 0.483 | 0.153 – 1.526 | 0.215 |
| Reflux esophagitis grade B | 15 (0.7 %) | 6 (0.28 %) | 9 (0.42 %) | 0.450 | 0.159 – 1.268 | 0.131 |
| Reflux esophagitis grade C | 37 (1.8 %) | 23 (1.1 %) | 14 (0.7 %) | 1.117 | 0.571 – 2.184 | 0.746 |
| Reflux esophagitis grade D | 29 (1.4 %) | 25 (1.2 %) | 4 (0.2 %) | 4.311 | 1.495 – 12.434 | 0.007 |
| Barrett esophagus | 129 (6.4 %) | 73 (3.6 %) | 56 (2.8 %) | 0.877 | 0.612 – 1.258 | 0.476 |
| Esophageal candidiasis | 30 (1.6 %) | 24 (1.3 %) | 6 (0.3 %) | 2.750 | 1.119 – 6.757 | 0.027 |
| Hiatal hernia | 22 (1.1 %) | 19 (0.95 %) | 3 (0.15 %) | 4.351 | 1.283 – 14.753 | 0.018 |
| Ulcus ventriculi | 20 (1 %) | 16 (0.8 %) | 4 (0.2 %) | 2.738 | 0.912 – 8.219 | 0.073 |
| Gastritis | 19 (0.9 %) | 13 (0.6 %) | 6 (0.3 %) | 1.476 | 0.559 – 3.898 | 0.432 |
| Ulcus duodeni | 17 (0.8 %) | 12 (0.6 %) | 5 (0.2 %) | 1.635 | 0.574 – 4.659 | 0.357 |
| Other | 58 (2.9 %) | 48 (2.4 %) | 10 (0.5 %) | 3.352 | 1.686 – 6.665 | 0.001 |
|
| 1514 (75.5 %) | 831 (41.4 %) | 683 (34.1 %) | 0.428 | 0.342 – 0.536 | < 0.0001 |
| Reflux esophagitis grade A | 152 (7.6 %) | 79 (3.9 %) | 73 (3.7 %) | 0.716 | 0.514 – 0.997 | 0.048 |
| Reflux esophagitis grade B | 94 (4.7 %) | 47 (2.3 %) | 47 (2.3 %) | 0.666 | 0.440 – 1.007 | 0.054 |
| Schatzki ring | 42 (2.1 %) | 38 (1.9 %) | 4 (0.2 %) | 6.626 | 2.356 – 18.638 | < 0.0001 |
| Hiatal hernia | 236 (11.7 %) | 128 (6.4 %) | 108 (5.3 %) | 0.781 | 0.594 – 1.026 | 0.076 |
| Fundic gland polyposis | 48 (2.4 %) | 29 (1.4 %) | 19 (1 %) | 1.037 | 0.577 – 1.862 | 0.904 |
| Gastritis | 176 (8.7 %) | 99 (4.9 %) | 77 (3.8 %) | 0.861 | 0.630 – 1.176 | 0.348 |
| Duodenitis | 40 (2.0 %) | 22 (1.1 %) | 18 (0.9 %) | 0.826 | 0.440 – 1.550 | 0.552 |
| Normal | 722 (36.0 %) | 385 (19.2 %) | 337 (16.8 %) | 0.669 | 0.556 – 0.804 | < 0.0001 |
| Other | 4 (0.3 %) | 4 (0.3 %) | 0 (0 %) | |||
|
| 2006 (100 %) | 1195 (59.6 %) | 811 (40.4 %) |
Only the outcomes occurring with a frequency > 0.5 % were extensively reported.
Uni- and multivariate logistic regression analysis of possible predictors for a clinical relevant endoscopy outcome.
| Clinical relevant endoscopy outcome | ||||||
|
|
| |||||
|
|
|
|
|
|
|
|
| Appropriate referral indication | 2.337 | 1.866 – 2.928 | < 0.0001 | 1.565 | 1.075 – 2.280 | 0.020 |
| Age | 1.037 | 1.029 – 1.045 | < 0.0001 | 1.023 | 1.010 – 1.037 | 0.001 |
| Gender | ||||||
Female | Reference | |||||
Male | 2.071 | 1.684 – 2.547 | < 0.0001 | 1.785 | 1.306 – 2.438 | < 0.0001 |
| PPI or H2RA use | ||||||
Yes | Reference | |||||
No | 1.817 | 1.445 – 2.285 | < 0.0001 | 1.292 | 0.877 – 1.903 | 0.195 |
| HP status | ||||||
Negative | Reference | |||||
Positive | 2.724 | 1.786 – 4.154 | < 0.0001 | 2.767 | 1.757 – 4.357 | < 0.0001 |
| Sedation | ||||||
Yes | 0.900 | 0.728 – 1.113 | 0.332 | |||
No | Reference | |||||
Details of the 4 patients with malignant disease without a referral indication according to the guideline.
|
|
|
|
|
|
|
|
|
| 1 | Woman | 81 | No | Yes | Unknown | Nausea | Esophageal carcinoma |
| 2 | Man | 80 | Unknown | Yes | Unknown | Epigastric pain | Esophageal carcinoma |
| 3 | Man | 69 | No | Yes | Unknown | Epigastric pain | Esophageal carcinoma |
| 4 | Woman | 70 | No | Yes | Negative | Cough | Malignancy of the stomach |
Sensitivity, specificity, positive and negative predictive value of every referral indication for different endoscopic outcome categories.
|
|
|
|
|
|
|
| Indication according to the NHG guideline | Malignant | 96.2 % (90.4 %-98.9 %) | 42.4 % (40.2 %-44.7 %) | 8.4 % (8.0 %-8.8 %) | 99.5 % (98.7 %-99.8 %) |
| Benign with clinical relevance | 68.0 % (63.2 %-72.7 %) | 42.5 % (40.0 %-44.9 %) | 22.1 % (20.8 %-23.5 %) | 84.7 % (82.6 %-86.6 %) | |
| Benign without clinical relevance | 54.9 % (52.3 %-57.4 %) | 26.0 % (22.2 %-30.1 %) | 69.5 % (68.1 %-71.0 %) | 15.8 % (13.8 %-18.0 %) | |
| Alarm symptoms overall | Malignant | 90.4 % (83.0 %-95.3 %) | 63.0 % (60.8 %-65.2 %) | 11.8 % (10.9 %-12.7 %) | 99.2 % (98.5 %-99.5 %) |
| Benign with clinical relevance | 51.6 % (46.5 %-56.6 %) | 63.1 % (60.7 %-65.5 %) | 25.1 % (23.0 %-27.3 %) | 84.5 % (83.0 %-85.8 %) | |
| Benign without clinical relevance | 33.2 % (30.9 %-35.7 %) | 40.2 % (35.9 %-44.7 %) | 63.1 % (60.7 %-65.5 %) | 16.4 % (14.9 %-18.0 %) | |
| Dysphagia | Malignant | 36.5 % (27.3 %-46.6 %) | 79.9 % (78.0 %-81.7 %) | 9.1 % (7.1 %-11.5 %) | 95.8 % (95.2 %-96.4 %) |
| Benign with clinical relevance | 29.1 % (24.6 %-33.9 %) | 81.0 % (79.0 %-82.9 %) | 26.9 % (23.4 %-30.7 %) | 82.7 % (81.7 %-83.6 %) | |
| Benign without clinical relevance | 17.8 % (15.9 %-19.8 %) | 69.3 % (65.0 %-73.4 %) | 64.1 % (60.0 %-67.9 %) | 21.5 % (20.5 %-22.6 %) | |
| Weight loss | Malignant | 9.6 % (4.7 %-17.0 %) | 95.1 % (94.0 %-96.0 %) | 9.6 % (5.4 %-16.5 %) | 95.1 % (94.8 %-95.4 %) |
| Benign with clinical relevance | 5.4 % (3.4 %-8.2 %) | 94.9 % (93.7 %-95.9 %) | 20.2 % (13.7 %-28.8 %) | 80.7 % (80.3 %-81.1 %) | |
| Benign without clinical relevance | 4.8 % (3.8 %-6.0 %) | 93.7 % (91.2 %-95.7 %) | 70.2 % (61.0 %-78.0 %) | 24.2 % (23.7 %-24.7 %) | |
| Gastrointestinal bleeding | Malignant | 3.9 % (1.1 %-9.6 %) | 95.4 % (94.3 %-96.3 %) | 4.4 % (1.7 %-10.8 %) | 94.8 % (94.6 %-95.0 %) |
| Benign with clinical relevance | 5.7 % (3.6 %-8.5 %) | 95.7 % (94.6 %-96.6 %) | 23.9 % (16.5 %-33.4 %) | 80.9 % (80.5 %-81.3 %) | |
| Benign without clinical relevance | 4.4 % (3.4 %-5.5 %) | 94.7 % (92.4 %-96.5 %) | 71.7 % (62.0 %-79.8 %) | 24.4 % (23.9 %-24.8 %) | |
| Anemia | Malignant | 1.9 % (0.2 %-6.8 %) | 98.5 % (97.8 %-99.0 %) | 6.5 % (1.6 %-22.2 %) | 94.8 % (94.7 %-95.0 %) |
| Benign with clinical relevance | 2.3 % (1.1 %-4.4 %) | 98.6 % (98.0 %-99.2 %) | 29.0 % (16.0 %-46.9 %) | 80.8 % (80.6 %-81.1 %) | |
| Benign without clinical relevance | 1.3 % (0.8 %-2.0 %) | 97.8 % (96.0 %-98.9 %) | 64.5 % (46.7 %-79.0 %) | 24.4 % (24.1 %-24.6 %) | |
| Dysphagia and weight loss | Malignant | 32.7 % (23.8 %-42.6 %) | 95.4 % (94.4 %-96.3 %) | 28.1 % (21.7 %-35.5 %) | 96.3 % (95.8 %-96.7 %) |
| Benign with clinical relevance | 7.2 % (4.9 %-10.3 %) | 94.3 % (93.0 %-95.3 %) | 23.1 % (16.7 %-31.2 %) | 80.9 % (80.4 %-81.4 %) | |
| Benign without clinical relevance | 3.9 % (3.0 %-5.0 %) | 87.4 % (84.1 %-90.2 %) | 48.8 % (40.3 %-57.3 %) | 22.8 % (22.2 %-23.4 %) | |
| Weight loss and gastrointestinal bleeding | Malignant | 1.0 % (0.02 %-5.2 %) | 99.4 % (99.0 %-99.7 %) | 8.3 % (1.2 %-41.1 %) | 94.8 % (94.7 %-94.9 %) |
| Benign with clinical relevance | 1.0 % (0.3 %-2.6 %) | 99.5 % (99.0 %-99.8 %) | 33.3 % (13.1 %-62.3 %) | 80.7 % (80.6 %-80.9 %) | |
| Benign without clinical relevance | 0.5 % (0.2 %-1.0 %) | 99.0 % (97.6 %-99.7 %) | 58.3 % (30.9 %-81.5 %) | 24.4 % (24.3 %-24.6 %) | |
| Dyspepsia > 50 years of age, HP negative | Malignant | 5.8 % (2.2 %-12.1 %) | 80.2 % (78.3 %-82.0 %) | 1.6 % (0.7 %-3.4 %) | 94.0 % (93.7 %-94.3 %) |
| Benign with clinical relevance | 16.0 % (12.5 %-20.0 %) | 80.2 % (78.1 %-82.1 %) | 16.2 % (13.1 %-19.9 %) | 79.9 % (79.1 %-80.7 %) | |
| Benign without clinical relevance | 20.8 % (18.8 %-22.9 %) | 86.2 % (82.8 %-89.1 %) | 82.3 % (78.4 %-85.5 %) | 26.1 % (25.3 %-27.0 %) | |
| Other | Malignant | 4.8 % (1.6 %-10.9 %) | 98.6 % (97.9 %-99.1 %) | 15.6 % (6.8 %-32.0 %) | 95.0 % (94.8 %-95.2 %) |
| Benign with clinical relevance | 1.3 % (0.4 %-3.0 %) | 98.3 % (97.6 %-98.9 %) | 15.6 % (6.7 %-32.3 %) | 80.6 % (80.4 %-80.8 %) | |
| Benign without clinical relevance | 1.5 % (0.9 %-2.2 %) | 98.0 % (96.3 %-99.0 %) | 68.8 % (51.2 %-82.2 %) | 24.4 % (24.2 %-24.7 %) | |
| Indication not according to the NHG guideline | Malignant | 3.9 % (1.1 %-9.6 %) | 57.6 % (55.3 %-59.8 %) | 0.5 % (0.2 %-1.3 %) | 91.6 % (91.2 %-92.0 %) |
| Benign with clinical relevance | 32.0 % (27.3 %-36.9 %) | 57.5 % (55.1 %-60.0 %) | 15.3 % (13.4 %-17.4 %) | 77.9 % (76.5 %-79.3 %) | |
| Benign without clinical relevance | 45.1 % (42.6 %-47.7 %) | 74.0 % (69.9 %-77.8 %) | 84.2 % (82.0 %-86.2 %) | 30.5 % (29.0 %-32.0 %) | |
| Dyspepsia < 50 years of age | Malignant | 0 % | 80.4 % (78.5 %-82.2 %) | 0 % | 93.6 % (93.5 %-93.8 %) |
| Benign with clinical relevance | 10.1 % (7.3 %-13.5 %) | 79.4 % (77.3 %-81.3 %) | 10.5 % (7.9 %-13.8 %) | 78.6 % (77.9 %-79.3 %) | |
| Benign without clinical relevance | 22.1 % (20.0 %-24.2 %) | 92.1 % (89.3 %-94.3 %) | 89.5 % (86.2 %-92.2 %) | 27.7 % (27.0 %-28.5 %) | |
| Dyspepsia > 50 years of age, HP unknown | Malignant | 3.9 % (1.1 %-9.6 %) | 77.8 % (75.8 %-79.6 %) | 0.94 % (0.36 %-2.42 %) | 93.7 % (93.4 %-93.9 %) |
| Benign with clinical relevance | 21.1 % (17.2 %-25.5 %) | 78.7 % (76.6 %-80.7 %) | 19.2 % (16.1 %-22.7 %) | 80.6 % (79.7 %-81.5 %) | |
| Benign without clinical relevance | 22.5 % (20.4 %-24.7 %) | 82.5 % (78.9 %-85.8 %) | 79.9 % (76.2 %-83.1 %) | 25.7 % (24.8 %-26.7 %) | |
| Other | Malignant | 0 % | 99.4 % (99.0 %-99.7 %) | 0 % | 94.8 % (94.8 %-94.8 %) |
| Benign with clinical relevance | 0.8 % (0.2 %-2.2 %) | 99.5 % (99.0 %-99.8 %) | 27.3 % (9.1 %-58.5 %) | 80.7 % (80.6 %-80.9 %) | |
| Benign without clinical relevance | 0.5 % (0.2 %-1.0 %) | 99.4 % (98.2 %-99.9 %) | 72.7 % (41.5 %-90.9 %) | 24.5 % (24.4 %-24.7 %) |
Only the indications occurring with a frequency > 0.5 % were extensively reported.
Uni- and multivariate logistic regression of possible predictors for upper gastrointestinal malignancy.
| Malignancy of the upper gastrointestinal tract | ||||||
|
|
| |||||
|
|
|
|
|
|
|
|
| Alarm symptoms | 16.032 | 8.298 – 30.974 | < 0.0001 | 10.488 | 5.276 – 20.849 | < 0.0001 |
| Age | 1.071 | 1.052 – 1.090 | < 0.0001 | 1.051 | 1.032 – 1.071 | < 0.0001 |
| Gender | ||||||
Female | Reference | |||||
Male | 4.481 | 2.796 – 7.183 | < 0.0001 | 3.942 | 2.401 – 6.473 | < 0.0001 |
| PPI or H2RA use | ||||||
Yes | Reference | |||||
No | 1.828 | 1.193 – 2.802 | 0.006 | 0.769 | 0.484 – 1.221 | 0.266 |
| HP status | ||||||
Negative | Reference | |||||
Positive | 0.825 | 0.191 – 3.569 | 0.797 | |||
| Sedation | ||||||
Yes | 0.810 | 0.541 – 1.214 | 0.308 | |||
No | Reference | |||||
Fig. 1Number of OAEs performed in different age groups.
Fig. 2Outcome of endoscopy in different age groups.
Fig. 3Receiver operating characteristic (ROC) curve comparing the accuracy of age alone (AUC = 0.729), alarm symptoms alone (AUC = 0.767) and age, alarm symptoms and male gender combined (AUC = 0.868) in predicting a malignant finding in OAE.